Cargando…
Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy
Circulating tumor cells (CTCs) were discovered nearly 150 years ago but have only recently been recognized as a feature of most solid tumors due to their extremely low concentration in the peripheral circulation. Several technologies have been developed to isolate and analyze CTCs, which can now be...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621388/ https://www.ncbi.nlm.nih.gov/pubmed/23589716 http://dx.doi.org/10.1155/2013/702732 |
_version_ | 1782265697351499776 |
---|---|
author | Alemar, Jose Schuur, Eric R. |
author_facet | Alemar, Jose Schuur, Eric R. |
author_sort | Alemar, Jose |
collection | PubMed |
description | Circulating tumor cells (CTCs) were discovered nearly 150 years ago but have only recently been recognized as a feature of most solid tumors due to their extremely low concentration in the peripheral circulation. Several technologies have been developed to isolate and analyze CTCs, which can now be routinely accessed for clinical information. The most mature of these (the CELLSEARCH system) uses immunomagnetic selection of epithelial cell adhesion molecule to isolate CTCs for analysis. Studies using this system have demonstrated that categorization of patients into high and low CTC groups using a validated decision point is prognostic in patients with metastatic breast, colorectal, or prostate cancer. Initial attempts to use CTC counts to guide therapeutic decisions appeared to yield positive results and key concepts in clinical application of CTC information, including the CTC cutoff, predictive value in disease subtypes, and comparison to current evaluation methods, have been demonstrated. Clinical studies of the impact of CTC counts in routine clinical practice are ongoing; however, recent published evidence on the clinical use of CTCs in metastatic breast cancer continues to support these concepts, and experience in the community oncology setting also suggests that CTC enumeration can be useful for therapy management. |
format | Online Article Text |
id | pubmed-3621388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36213882013-04-15 Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy Alemar, Jose Schuur, Eric R. J Oncol Review Article Circulating tumor cells (CTCs) were discovered nearly 150 years ago but have only recently been recognized as a feature of most solid tumors due to their extremely low concentration in the peripheral circulation. Several technologies have been developed to isolate and analyze CTCs, which can now be routinely accessed for clinical information. The most mature of these (the CELLSEARCH system) uses immunomagnetic selection of epithelial cell adhesion molecule to isolate CTCs for analysis. Studies using this system have demonstrated that categorization of patients into high and low CTC groups using a validated decision point is prognostic in patients with metastatic breast, colorectal, or prostate cancer. Initial attempts to use CTC counts to guide therapeutic decisions appeared to yield positive results and key concepts in clinical application of CTC information, including the CTC cutoff, predictive value in disease subtypes, and comparison to current evaluation methods, have been demonstrated. Clinical studies of the impact of CTC counts in routine clinical practice are ongoing; however, recent published evidence on the clinical use of CTCs in metastatic breast cancer continues to support these concepts, and experience in the community oncology setting also suggests that CTC enumeration can be useful for therapy management. Hindawi Publishing Corporation 2013 2013-03-25 /pmc/articles/PMC3621388/ /pubmed/23589716 http://dx.doi.org/10.1155/2013/702732 Text en Copyright © 2013 J. Alemar and E. R. Schuur. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Alemar, Jose Schuur, Eric R. Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy |
title | Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy |
title_full | Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy |
title_fullStr | Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy |
title_full_unstemmed | Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy |
title_short | Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy |
title_sort | progress in using circulating tumor cell information to improve metastatic breast cancer therapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621388/ https://www.ncbi.nlm.nih.gov/pubmed/23589716 http://dx.doi.org/10.1155/2013/702732 |
work_keys_str_mv | AT alemarjose progressinusingcirculatingtumorcellinformationtoimprovemetastaticbreastcancertherapy AT schuurericr progressinusingcirculatingtumorcellinformationtoimprovemetastaticbreastcancertherapy |